# Relmada Therapeutics, Inc. (RLMD)

> Source: Nexqual · https://nexqual.com/RLMD · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Relmada Therapeutics, Inc. (RLMD), nexqual.com/RLMD" · informational, not investment advice.

**Price:** USD 3.2 (-1.23% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 3.24 · day 3.19–3.35 · 52w 1.8–8 · market cap $341M · NCM

## Key facts
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 10.75 (range 9–12).
- Total return with dividends: 1Y +59.2% vs S&P 500 +18.1%; 5Y -86.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.15, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 10.75 (low 9, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-18 | HC Wainwright & Co. | Initiated | Buy | $12 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +59.2% | -86.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +59.5% | -32.9% |
| Volatility (annualized) | 89.1% | 148.9% |
| Max drawdown | -59.7% (May 2026→Oct 2026) | -99.3% (Sep 2022→Feb 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/RLMD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt